Age-related variation in the relationship between menopausal hormone therapy and the risk of dying from breast cancer

Breast Cancer Research and Treatment

Volumn 126, Issue 3, 2011, Pages 749-761

  Reding, Kerryn W ^a,b   Doody, David R ^b   McTiernan, Anne ^a,b   Hsu, Li ^b   Davis, Scott ^a,b   Daling, Janet R ^b   Porter, Peggy L ^b   Malone, Kathleen E ^b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

Author keywords

Breast cancer; Hormone therapy; Mortality; Prognosis

Indexed keywords

ESTROGEN; GESTAGEN;

ADULT; AGE; AGED; ARTICLE; BREAST CANCER; CANCER INVASION; CANCER MORTALITY; CANCER STAGING; CONTROLLED STUDY; DRUG USE; DYING; FEMALE; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; MAMMOGRAPHY; MENOPAUSAL SYNDROME; POPULATION RESEARCH; PRIORITY JOURNAL; PROGNOSIS; RISK REDUCTION;

EID: 85027950834     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-010-1174-7     Document Type: Article

References (36)

1. Adami HO, Malker B, Holmberg L, Persson I, Stone B (1986) The relation between survival and age at diagnosis in breast cancer. N Engl J Med 315(9):559-563 (Pubitemid 16052469)
2. Antoine C, Liebens F, Carly B, Pastijn A, Rozenberg S (2004) Influence of HRT on prognostic factors for breast cancer: a systematic review after the Women's Health Initiative trial. Hum Reprod 19(3):741-756 (Pubitemid 38344544)
3. Biglia N, Sgro L, Defabiani E, De RG, Ponzone R, Marenco D, Sismondi P (2005) The influence of hormone replacement therapy on the pathology of breast cancer. Eur J Surg Oncol 31(5):467-472 (Pubitemid 40724085)
4. Boudreau DM, Daling JR, Malone KE, Gardner JS, Blough DK, Heckbert SR (2004) A validation study of patient interview data and pharmacy records for antihypertensive, statin, and antide-pressant medication use among older women. Am J Epidemiol 159(3):308-317 (Pubitemid 38141661)
5. Chen W, Petitti DB, Geiger AM (2005) Mortality following development of breast cancer while using oestrogen or oestrogen plus progestin: a computer record-linkage study. Br J Cancer 93(4):392-398 (Pubitemid 43080011)
6. Chlebowski RT, Hendrix SL, Langer RD, Stefanick ML, Gass M, Lane D, Rodabough RJ, Gilligan MA, Cyr MG, Thomson CA, Khandekar J, Petrovitch H, McTiernan A (2003) Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA 289(24):3243-3253 (Pubitemid 37430077)
7. Christante D, Pommier S, Garreau J, Muller P, LaFleur B, Pommier R (2008) Improved breast cancer survival among hormone replacement therapy users is durable after 5 years of additional follow-up. Am J Surg 196(4):505-511
8. Cluze C, Colonna M, Remontet L, Poncet F, Sellier E, Seigneurin A, Delafosse P, Bossard N (2009) Analysis of the effect of age on the prognosis of breast cancer. Breast Cancer Res Treat 117(1): 121-129
9. Colditz GA, Hankinson SE, Hunter DJ, Willett WC, Manson JE, Stampfer MJ, Hennekens C, Rosner B, Speizer FE (1995) The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 332(24):1589-1593
10. Daling JR, Malone KE, Doody DR, Voigt LF, Bernstein L, Coates RJ, Marchbanks PA, Norman SA, Weiss LK, Ursin G, Berlin JA, Burkman RT, Deapen D, Folger SG, McDonald JA, Simon MS, Strom BL, Wingo PA, Spirtas R (2002) Relation of regimens of combined hormone replacement therapy to lobular, ductal, and other histologic types of breast carcinoma. Cancer 95(12):2455-2464 (Pubitemid 35424029)
11. Daling JR, Malone KE, Doody DR, Voigt LF, Bernstein L, Marchbanks PA, Coates RJ, Norman SA, Weiss LK, Ursin G, Burkman RT, Deapen D, Folger SG, McDonald JA, Simon MS, Strom BL, Spirtas R (2003) Association of regimens of hormone replacement therapy to prognostic factors among women diagnosed with breast cancer aged 50-64 years. Cancer Epidemiol Biomarkers Prev 12(11 Pt 1):1175-1181 (Pubitemid 37499440)
12. Davis S, Mirick DK, Stevens RG (2001) Night shift work, light at night, and risk of breast cancer. J Natl Cancer Inst 93(20): 1557-1662
13. Davis S, Mirick DK, Stevens RG (2002) Residential magnetic fields and the risk of breast cancer. Am J Epidemiol 155(5): 446-454 (Pubitemid 34174156)
14. Delgado RC, Lubian Lopez DM (2001) Prognosis of breast cancers detected in women receiving hormone replacement therapy. Maturitas 38(2):147-156 (Pubitemid 32295928)
15. Gapstur SM, Morrow M, Sellers TA (1999) Hormone replacement therapy and risk of breast cancer with a favorable histology: results of the Iowa Women's Health Study. JAMA 281(22): 2091-2097
16. Hall P, Ploner A, Bjohle J, Huang F, Lin CY, Liu ET, Miller LD, Nordgren H, Pawitan Y, Shaw P, Skoog L, Smeds J, Wedren S, Ohd J, Bergh J (2006) Hormone-replacement therapy influences gene expression profiles and is associated with breast-cancer prognosis: a cohort study. BMC Med 4:16
17. Holli K, Isola J (1997) Effect of age on the survival of breast cancer patients. Eur J Cancer 33(3):425-428 (Pubitemid 27168069)
18. Jernstrom H, Frenander J, Ferno M, Olsson H (1999) Hormone replacement therapy before breast cancer diagnosis significantly reduces the overall death rate compared with never-use among 984 breast cancer patients. Br J Cancer 80(9):1453-1458 (Pubitemid 29308617)
19. Khan HN, Bendall S, Bates T (2007) Is hormone replacement therapy-related breast cancer more favorable? A case-control study. Breast J 13(5):496-500 (Pubitemid 47329338)
20. Li CI, Malone KE, Porter PL, Weiss NS, Tang MT, Cushing-Haugen KL, Daling JR (2003) Relationship between long durations and different regimens of hormone therapy and risk of breast cancer. JAMA 289(24):3254-3263 (Pubitemid 37430078)
21. Longnecker MP, Bernstein L, Paganini-Hill A, Enger SM, Ross RK (1996) Risk factors for in situ breast cancer. Cancer Epidemiol Biomarkers Prev 5(12):961-965 (Pubitemid 26415867)
22. Louwman WJ, Voogd AC, van Dijck JA, Nieuwenhuijzen GA, Ribot J, Pruijt JF, Coebergh JW (2008) On the rising trends of incidence and prognosis for breast cancer patients diagnosed 1975-2004: a long-term population-based study in southeastern Netherlands. Cancer Causes Control 19(1):97-106
23. Magnusson C, Holmberg L, Norden T, Lindgren A, Persson I (1996) Prognostic characteristics in breast cancers after hormone replacement therapy. Breast Cancer Res Treat 38(3):325-334 (Pubitemid 26126667)
24. Marchbanks PA, McDonald JA, Wilson HG, Burnett NM, Daling JR, Bernstein L, Malone KE, Strom BL, Norman SA, Weiss LK, Liff JM, Wingo PA, Burkman RT, Folger SG, Berlin JA, Deapen DM, Ursin G, Coates RJ, Simon MS, Press MF, Spirtas R (2002) The NICHD Women's Contraceptive and Reproductive Experiences Study: methods and operational results. Ann Epidemiol 12(4):213-221 (Pubitemid 34414934)
25. Nanda K, Bastian LA, Schulz K (2002) Hormone replacement therapy and the risk of death from breast cancer: a systematic review. Am J Obstet Gynecol 186(2):325-334 (Pubitemid 34165456)
26. Newcomb PA, Egan KM, Trentham-Dietz A, Titus-Ernstoff L, Baron JA, Hampton JM, Stampfer MJ, Willett WC (2008) Prediagnostic use of hormone therapy and mortality after breast cancer. Cancer Epidemiol Biomarkers Prev 17(4):864-871 (Pubitemid 351536417)
27. Onega T, MacKenzie T, Weiss J, Goodrich M, Titus-Ernstoff L (2010) Screening mammography intervals among postmeno-pausal hormone therapy users and nonusers. Cancer Causes Control 21(1):147-152
28. Prentice RL, Manson JE, Langer RD, Anderson GL, Pettinger M, Jackson RD, Johnson KC, Kuller LH, Lane DS, Wactawski-Wende J, Brzyski R, Allison M, Ockene J, Sarto G, Rossouw JE (2009) Benefits and risks of postmenopausal hormone therapy when it is initiated soon after menopause. Am J Epidemiol 170:12-23
29. Rosenberg LU, Granath F, Dickman PW, Einarsdottir K, Wedren S, Persson I, Hall P (2008) Menopausal hormone therapy in relation to breast cancer characteristics and prognosis: a cohort study. Breast Cancer Res 10(5):R78
30. Schairer C, Gail M, Byrne C, Rosenberg PS, Sturgeon SR, Brinton LA, Hoover RN (1999) Estrogen replacement therapy and breast cancer survival in a large screening study. J Natl Cancer Inst 91(3):264-270 (Pubitemid 29090996)
31. Sener SF, Winchester DJ, Winchester DP, Du H, Barrera E, Bilimoria M, Krantz S, Rabbitt S (2009) The effects of hormone replacement therapy on postmenopausal breast cancer biology and survival. Am J Surg 197(3):403-407
32. Slanger TE, Chang-Claude JC, Obi N, Kropp S, Berger J, Vettorazzi E, Braendle W, Bastert G, Hentschel S, Flesch-Janys D (2009) Menopausal hormone therapy and risk of clinical breast cancer subtypes. Cancer Epidemiol Biomarkers Prev 18(4): 1188-1196
33. Stanford JL, Weiss NS, Voigt LF, Daling JR, Habel LA, Rossing MA (1995) Combined estrogen and progestin hormone replacement therapy in relation to risk of breast cancer in middle-aged women. JAMA 274(2):137-142
34. Strickland DM, Gambrell RD, Butzin CA, Strickland K (1992) The relationship between breast cancer survival and prior post-menopausal estrogen use. Obstet Gynecol 80(3 Pt 1):400-404
35. Ugnat AM, Xie L, Morriss J, Semenciw R, Mao Y (2004) Survival of women with breast cancer in Ottawa, Canada: variation with age, stage, histology, grade and treatment. Br J Cancer 90(6):1138-1143 (Pubitemid 38496804)
36. Ziogas A, Anton-Culver H (2003) Validation of family history data in cancer family registries. Am J Prev Med 24(2):190-198 (Pubitemid 36144098)